Provided by Tiger Fintech (Singapore) Pte. Ltd.

iHuman

1.89
-0.0700-3.57%
Volume:1.89K
Turnover:3.40K
Market Cap:98.31M
PE:7.66
High:1.89
Open:1.76
Low:1.76
Close:1.96
Loading ...

The recent 11% gain must have brightened Top Key Executive Yufeng Chi's week, iHuman Inc.'s (NYSE:IH) most bullish insider

Simply Wall St.
·
28 Feb

Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance

PR Newswire
·
26 Feb

Avadel Pharmaceuticals Appoints Kevin Springman as Vice President of Sales

GlobeNewswire
·
24 Feb

Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder

Benzinga
·
20 Feb

Harmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia

Business Wire
·
19 Feb

Press Release: Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates

Dow Jones
·
14 Feb

Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board

GlobeNewswire
·
04 Feb

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire
·
28 Jan

Incannex Healthcare Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X, an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea

GlobeNewswire
·
23 Jan

ZCCM-IH Announces Board Change with Departure of Non-Executive Director

TIPRANKS
·
21 Jan

Why Is Centessa Pharmaceuticals (CNTA) Among the Best Medical Stocks to Buy Under $20?

Insider Monkey
·
13 Jan

AE50 2025: Ten Ag innovations from CNH awarded by ASABE

GlobeNewswire
·
09 Jan

Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ Launch

GlobeNewswire
·
09 Jan

Press Release: Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer

Dow Jones
·
08 Jan

iHuman Inc. Reports Q3 2024 Financial Results and Strategic Expansions

TIPRANKS
·
26 Dec 2024

iHuman's Q3 MAUs Rose 14.8% YoY To 29.12M

Benzinga
·
26 Dec 2024

iHuman Q3 Adj EPADS $0.07 Down From $0.14 YoY, Sales $34.12M Down From $35.84M YoY

Benzinga
·
26 Dec 2024

BRIEF-Ihuman Q3 Diluted Net Income Per ADS US$0.07

Reuters
·
26 Dec 2024

Ihuman Q3 Gross Margin 68.4%

THOMSON REUTERS
·
26 Dec 2024

Ihuman Q3 Operating Expenses RMB 143.2 Million

THOMSON REUTERS
·
26 Dec 2024